Carcinoma Progression Articles & Analysis
2 news found
In 22/24 patient tests (91%), the results demonstrated resistance to at least one drug on which the patient’s disease progressed in clinic. The PARIS® Test showed good clinical response concordant with assay results for 10/12 patients (83%) evaluated for clinical prediction. ...
BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA for first-line treatment of patients with advanced renal cell carcinoma (RCC) Phase III study showed combination significantly lowered risk of disease progression or death by 31% and extended progression-free survival by 5.4 months for patients with advanced RCC ...